metaPreg - Lorazepam during pregnancy

Lorazepam updated on 02-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
Ano-rectal atresia and stenosis	3.29 [0.48, 22.44]	49%	2 studies	1,308	7	not evaluable	ROB	-
Congenital heart defects	1.15 [0.94, 1.41]	0%	2 studies	95,880	2,489	not evaluable	ROB	-
Oro-facial clefts	-	-	0 study					-
Pulmonary valve stenosis	4.10 [1.19, 14.10]	-	1 study	1,532	11	not evaluable	ROB	7.67 [1.67; .]
22 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.99 [0.46, 19.38]	98%	2 studies	263,495	11,093	not evaluable	ROB	-
Small for gestational age (weight)	1.18 [1.11, 1.25]	-	1 study	263,221	11,020	not evaluable	ROB	1.64 [1.46; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.48 [1.23, 1.79]	54%	3 studies	45,219	896	not evaluable	ROB	2.33 [1.75; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths	1.31 [1.11, 1.54]	-	1 study	30,858	11,182	not evaluable	ROB	1.95 [1.47; .]